sotorasib + RMC-4630

**Sotorasib + RMC-4630** is a combination regimen of two investigational small molecule drugs targeting advanced cancers with KRAS G12C mutations, especially in non-small cell lung cancer (NSCLC)[1][3][5]. Sotorasib is a selective, covalent inhibitor of KRAS G12C developed to block oncogenic KRAS signaling. RMC-4630 (also known as Vociprotafib, SAR442720) is a selective, orally bioavailable allosteric inhibitor of protein tyrosine phosphatase non-receptor type 11 (PTPN11, commonly called SHP2), developed to block signaling upstream of KRAS, thereby further inhibiting downstream MAPK signaling and potentially enhancing the activity of KRAS G12C inhibitors[4][2][5]. This combination has shown promise in overcoming resistance to KRAS G12C inhibitors[5]. Developed primarily for patients with advanced KRAS G12C-mutated NSCLC, the combination is being evaluated in multi-phase clinical trials, often in patients who have failed prior standard therapies but not prior KRASG12C or SHP2 inhibitors[1][5].

Brand names

Lumakras

Other names

Sotorasib + SHP2 inhibitorSotorasib + VociprotafibSotorasib + SAR442720